- Home >
- Clinicals Trials >
- LYNPARZA (D0816C000025)
Childhood and adolescent cancers
LYNPARZA (D0816C000025)
A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety;and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with;Solid Tumours
- Open at Paris since : 16/06/2020
- Target : Child
- Phase : Phase I
Trial description
Polyadenosine 5Àdiphosphoribose;[poly (ADP ribose)] polymerisation (PARP) inhibition in adults who have platinum sensitive;relapsed epithelial ovarian cancer with and without homologous recombination deficiencies;(HRD) and in locally advanced or metastatic recurrent breast cancer harbouring deleterious or;suspected deleterious mutations of the breast cancer susceptibility genes (BRCA; BRCA1 and;BRCA2) has been identified as an effective treatment approach. PARP inhibition in paediatric;patients with non-central nervous system (CNS) solid tumours that harbour mutations in genes;involved in homologous recombination repair (HRR) may offer a novel alternative treatment;approach.
Url of the trial